Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2486)	8/13/2009 12:55:26 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

ANX is up 21.87% on volume already above 16,947,400 > 4x its ADV. The stock opened with an UG but is still trading below its Jun11 H of $0.25 <g> bigcharts.marketwatch.com It reported yesterday its 2ndQ results and said that they believe that they have the capital to complete and submit an NDA for their ANX-530 to the FDA later this year.<g> The loss for the 2ndQ was $3.8M ($0.04/shr) vs.$6.4M ($0.07/shr)in 2008. R&D expenses were $1.5M vs.$4.5M in 2008. The 'analyst consensus at Yahoo' (ACAY) is around $1.20 and it seems that with its lower burn rate, negligible LTD and some good news, the stock could get to close some of its Oct 2007 DG above the $1 level.<g> bigcharts.marketwatch.com Bernard